semaglutide type 1 diabetes automated insulin delivery randomized trial 2025 Subcutaneous weekly with in diabetes: a double-blind, randomized, crossover Semaglutide in Adults with Type

Food and Drug Administration (2023) Tirzepatide versus semaglutide once weekly in patients with Type 2 diabetes, The New England Journal of Medicine (2021) Johns Hopkins scientists say risk of pancreatitis doubles for those taking new class of diabetes drugs, John Hopkins Medicine (2013) Normal and disordered gastric emptying in diabetes: Recent insights into (patho)physiology, management and impact on glycaemic control, Diabetologia (2022) GLP-1 receptor agonists and the risk of thyroid cancer, American Diabetes Association (2022) Mounjaro highlights of prescribing information, The U.S

Another reason to work with a dietitian is to help manage potential side effects

Having a true allergic reaction is

One of the most promising options for weight loss is GLP-1, originally developed for type 2 diabetes but now gaining attention for its potential in nondiabetic patients